The findings suggest that GLP-1 agonists, such as exenatide, liraglutide, and semaglutide, offer renal protection and improve diabetic nephropathy, which is crucial given the high burden of renal complications in T2DM. This evidence concerns the gene GCG and diabetic kidney disease.